Xinan Wang

Biography

Education and Training

• B.S., Biomedical Engineering
  Tokyo Institute of Technology
• Ph.D., Population Health Sciences
  Harvard University
• M.S., Computational Biology and Quantitative Genetics
  Harvard T.H. Chan School of Public Health

Awards and Honors

• Young Investigator Award - SITC, 2024
  Society of Immunotherapy for Cancer
• Scholar-in-Training Award - AACR, 2024
  American Association for Cancer Research
• Early Career in Tobacco Control and Smoking Cessation Award - WCLC, 2023
  World Conference on Lung Cancer
• Reviewer's Choice Abstract - ASHG, 2023
  American Society of Human Genetics
• Harvard Presidential Scholarship, 2018 - 2019
  Harvard University

Publications

• Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.

  Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Pecci F, Makarem M, Gandhi MM, Garbo E, Saini A, De Giglio A, Favorito V, Scalera S, Cipriani L, Marinelli D, Haradon D, Nguyen T, Haradon J, Voligny E, Vaz V, Gelsomino F, Sperandi F, Melotti B, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Lindsay J, Rodig SJ, Pfaff K, Sholl LM, Wang X, Johnson BE, Jänne PA, Rekhtman N, Maugeri-Saccà M, Heist RS, Ardizzoni A, Awad MM, Arbour KC, Schoenfeld AJ, Vokes NI, Luo J. Ann Oncol 2024 Dec 03

• Automated Interstitial Lung Abnormality Probability Prediction at CT: A Stepwise Machine Learning Approach in the Boston Lung Cancer Study.

  Hata A, Aoyagi K, Hino T, Kawagishi M, Wada N, Song J, Wang X, Valtchinov VI, Nishino M, Muraguchi Y, Nakatsugawa M, Koga A, Sugihara N, Ozaki M, Hunninghake GM, Tomiyama N, Li Y, Christiani DC, Hatabu H. Radiology 2024 09

• RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.

  Nokin MJ, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, San José S, Peirone S, Caizzi L, Vietti Michelina S, Bourdon A, Wang X, Alvarez-Villanueva D, Martínez-Iniesta M, Vidal A, Rodrigues T, García-Macías C, Awad MM, Nadal E, Villanueva A, Italiano A, Cereda M, Santamaría D, Ambrogio C. Nat Commun 2024 Aug 30

• Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

  Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, Locquet MA, Gottlieb FH, Chen MF, Lee E, Haradon D, Smokovich A, Voligny E, Nguyen T, Goel VK, Zimmerman Z, Atwal S, Wang X, Bahcall M, Heist RS, Iqbal S, Gandhi N, Elliott A, Vanderwalde AM, Ma PC, Halmos B, Liu SV, Che J, Schrock AB, Drilon A, Jänne PA, Awad MM. Cancer Discov 2024 Aug 02

• Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.

  Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, Pecci F, Lamberti G, Gandhi MM, Vaz VR, Spurr LF, Sholl LM, Pfaff KL, Rodig SJ, Li YY, Cherniack AD, Nishino M, Johnson BE, Awad MM. Ann Oncol 2024